Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04392154 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,153
- Enrollment target
NCT04392154 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,153 participants.
The verdict
NCT04392154, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,153 participants
- Enrollment target
Study Summary
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Interventions
- BIOLOGICAL Lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,153 participants |
| Start Date | 2020-06-15 |
| Est. Completion | 2025-04-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04392154
The ClinicalTrials.gov registry entry for NCT04392154 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT04392154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04392154 about?
NCT04392154 is a clinical study titled "Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)". This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
What is the current status of trial NCT04392154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,153 participants. The study started on 2020-06-15. Estimated completion is 2025-04-22.
What interventions are being tested in trial NCT04392154?
The interventions under investigation include: Lebrikizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04392154?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.